Avoro Capital Advisors LLC

Institutional investor · Portfolio as of Q2 2026

Q2 2026 biggest moves
  • CYTKCYTK

    Cytokinetics

    Added 50%

    now 3.8% of portfolio

  • DFTXDFTX

    Definium Therapeutics

    Added 44%

    now 3.0% of portfolio

  • UTHRUTHR

    United Therapeutics

    Added 6%

    now 14% of portfolio

  • ALKSALKS

    Alkermes

    Sold out

    was 0.4% of portfolio

23 changes in all

Top Holdings26 positions

Checking export access…
Activity:
UTHR

United Therapeutics Corporation

2.8M$1.5B13.5%$248.82+117.76%
23 qtrssince 2020-Q4
Increased
67
ASND

Ascendis Pharma A/S

5.1M$1.4B12.2%$150.28+77.48%
8 qtrssince 2020-Q2
Increased
63
KRYS

Krystal Biotech, Inc.

2.9M$1.1B9.6%$105.41+252.59%
19 qtrssince 2021-Q4
Unchanged
0
MDGL

Madrigal Pharmaceuticals, Inc.

1.8M$984.4M8.8%$162.41+230.62%
30 qtrssince 2019-Q1
Increased
63
ARGX
ARGX
ADR

argenx SE

1M$927.8M8.3%$230.06+303.27%
30 qtrssince 2019-Q1
Unchanged
0
ARWR

Arrowhead Pharmaceuticals, Inc.

11.4M$925.6M8.3%$30.45+167.72%
13 qtrssince 2023-Q2
Increased
67
KYMR

Kymera Therapeutics, Inc.

7.5M$857.1M7.7%$39.18+192.71%
20 qtrssince 2021-Q3
Unchanged
0
RVMD

Revolution Medicines, Inc.

2.3M$430.2M3.9%$80.96+131.33%
3 qtrssince 2025-Q4
Decreased
0
CYTK

Cytokinetics, Incorporated

5M$425.9M3.8%$72.34+17.77%
2 qtrssince 2026-Q1
Increased
80
CELC

Celcuity Inc.

3.4M$355.7M3.2%$100.89+3.69%
3 qtrssince 2025-Q4
Increased
58
GPCR
GPCR
ADR

Structure Therapeutics Inc.

6.6M$351.8M3.2%$36.87+45.55%
4 qtrssince 2025-Q3
Unchanged
0
XENE

Xenon Pharmaceuticals Inc.

5.8M$348.7M3.1%——
30 qtrssince 2019-Q1
Unchanged
0
DFTX

Definium Therapeutics, Inc.

7.2M$338.2M3.0%$27.47+71.25%
2 qtrssince 2026-Q1
Increased
78
QURE

uniQure N.V.

6.7M$309.9M2.8%$26.47+74.00%
7 qtrssince 2024-Q4
Increased
61
VERA

Vera Therapeutics, Inc.

5.7M$245.6M2.2%$40.81+5.14%
10 qtrssince 2024-Q1
Decreased
0
TSHA

Taysha Gene Therapies, Inc.

23.9M$162.7M1.5%$3.15+115.88%
12 qtrssince 2023-Q3
Increased
54
OCUL

Ocular Therapeutix, Inc.

12.5M$123.1M1.1%$9.60+2.28%
10 qtrssince 2024-Q1
Increased
49
GLTO

DAMORA THERAPEUTICS INC

3.8M$98.4M0.9%$25.90-17.84%
2 qtrssince 2026-Q1
Unchanged
0
COAG

Hemab Therapeutics Holdings, Inc.

1.9M$70.7M0.6%$36.730.00%
1 qtr
New
59
GHRS

GH Research PLC

1.8M$48.4M0.4%$12.70+111.65%
3 qtrssince 2025-Q4
Unchanged
0
$11.1B
AUM
26
Positions
Q2 2026
Filing
HI rating · 3.5/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2025-Q1$6,406,567,714-9.38352778103%
2025-Q2$5,710,277,507-10.8683812938%
2025-Q3$7,736,501,04535.4838015406%
2025-Q4$10,174,376,43231.5113430842%
2026-Q1$10,164,789,055-0.0942306102401%
2026-Q2$11,136,250,1859.55712041582%
Activity profile
$ moved · Q2'26
New3%Increased44%Decreased7%Exited45%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.9 years
<1Q8%1-4Q31%1-2Y4%2Y+58%

Avoro Capital Advisors LLC manages $11.1B across 26 positions as of Q2 2026. Top holdings: UTHR (13.5%), ASND (12.2%), KRYS (9.6%). Fund DNA: Concentrated Value. HoldingsIntel Score: 3.5/5.0.

Top holdings by portfolio weight

Total AUM$11B
UTHR13.52%
ASND12.24%
KRYS9.64%
MDGL8.84%
ARGX8.33%
ARWR8.31%
KYMR7.70%
RVMD3.86%
CYTK3.82%
CELC3.19%
Other3.16%

Portfolio allocation by GICS sector

Sectors1
Healthcare100.00%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Strong(3.5 / 5.0)
Holdings P&L58
Conviction67
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
2Q
AVTXAVTXAvalo Therapeutics, Inc.
Q2 2026 → Q3 2026+967,777 shares+$15.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used